Scholarlink

Abilify Asimtufii® is a 2-month administration of aripiprazole monohydrate, which was approved utilizing well-controlled studies of Abilify Maintena® in the treatment of schizophrenia or maintenance treatment of bipolar I disorder in adults. The aripiprazole concentrations of Abilify Asimtufii® were studied in a pharmacokinetic bridging study through a 32-week, open-label, multiple-dose, randomized, parallel-arm, multicenter study (N = 266) in patients with schizophrenia and bipolar I disorder. Abilify Asimtufii® demonstrated sustained plasma concentrations comparable to Abilify Maintena® (Abilify Asimtufii® [package insert]. Otsuka, Pharmaceutical Co., Ltd., Tokyo, 2025). This chapter provides clinical pearls on how to appropriately prescribe and administer Abilify Asimtufii®.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aripiprazole Monohydrate (Abilify Asimtufii®): Second-Generation Antipsychotic Long-Acting Injectable

  • 章节

  • 发表日期：

    2025年

查看全文
  • Megan J. Ehret

摘要

Abilify Asimtufii® is a 2-month administration of aripiprazole monohydrate, which was approved utilizing well-controlled studies of Abilify Maintena® in the treatment of schizophrenia or maintenance treatment of bipolar I disorder in adults. The aripiprazole concentrations of Abilify Asimtufii® were studied in a pharmacokinetic bridging study through a 32-week, open-label, multiple-dose, randomized, parallel-arm, multicenter study (N = 266) in patients with schizophrenia and bipolar I disorder. Abilify Asimtufii® demonstrated sustained plasma concentrations comparable to Abilify Maintena® (Abilify Asimtufii® [package insert]. Otsuka, Pharmaceutical Co., Ltd., Tokyo, 2025). This chapter provides clinical pearls on how to appropriately prescribe and administer Abilify Asimtufii®.